



Lovo[®] Automated Cell Processing System

Flexible and precise closed-system cell washing and volume-reduction

With data driven insights and reporting powered by DXT[®] Data Management System

DXT
Move Efficiency
Forward



scaleready.com

Lovo supports your unique selection prep, thaw wash, or harvest wash processes.

Immunomagnetic Selection Prep¹

Remove platelets, incubate with beads, and remove unbound beads in a single procedure for fast and automated processing



Fresh Leukapheresis Wash²

Remove platelets with precision and resuspend your cells in a preferred buffer for any custom manufacturing process



Culture Harvest & Media Exchange³

Volume-reduce or exchange media for your expanded products with high cell recoveries and washout efficiency



Thawed Wash & DMSO Removal⁴

Wash cryopreserved products to remove DMSO and resuspend cells in your preferred buffer or culture media



Increase operational efficiency

Cells continually flow in and out of Lovo's spinning membrane module, minimizing overall processing time. Lovo handles source volumes up to 22 L and processes a standard apheresis product in approximately 11 minutes.³

Improve product consistency and quality

Capture precisely the cells you need, optimizing recovery while maintaining viability — even for fragile cells. The membrane's 4 μm pores enable >98% TNC recovery and <2% decrease in viability when targeting 99.9% supernatant removal.³


Choose filtered to further your goals.

Whether you're focused on early stage trials or ramping up to full commercialization, Lovo's spinning membrane filtration technology enables fast, precise, and flexible procedures that help increase your lab's overall operational efficiency and processing consistency without compromising product quality.² You can rely on Lovo and the ScaleReady team to work with you to address your lab's biggest challenges in developing cutting-edge cell therapy manufacturing solutions.

Customize protocols to fit your process

Lovo's software has been designed to support your unique processes and technologies. Up to 10 protocols can be saved on the device and each wash cycle may be customized even further.

Proprietary spinning membrane filtration technology



The Partnership of Data & Compliance


DXT® for use with the Lovo Cell Processing System



Lovo



DXT



End User

Electronically transfer procedure record data | Anytime, Anywhere Access

DXT is a Data Management Software application designed to receive, store and transmit procedure information

Information is transferred from Lovo to the DXT Data Management Software via a wired or wireless connection and can then be transferred to your external systems

Supports 21CFR Part 11 compliance

DXT Data Management System Requirements

Operating System	Windows 11 Pro	Windows Server 2019
Database Management System (DBMS)	SQL Server 2019 Express	SQL Server 2019
Processor	2 cores @ 2.3 GHz	4 cores @ 2.3 GHz
Memory	8 GB	16 GB
Disk Size*	500 GB SSD	500 GB SSD

* The disk size requirements will depend on organizational data retention policy for data immediately accessible through DXT.

Additional System Features

- LIMS interface compatible
- Technical support provided by Fresenius Kabi team

Procedure Report - Lovo

Location

Times (hh:mm:ss)	Estimated Total	Measured	Paused	Solution 2 (mL)	Estimated Total	Measured
Source Processing	01:17:02	01:47:40	00:43:11	304	304	314
Duration	01:20:49	01:20:49	00:03:00	200*	200	200
	00:00	00:00	00:00	2386	2386	2382
				Target Minimum Final Product Volume	200	200

Supernatant Removal

Estimated Total	Measured
99.9775	0.13

Incubation

Estimated Duration (HH:MM:SS)	Measured Automated Duration (HH:MM:SS)	Measured Total Duration (HH:MM:SS)	Estimated Volume (mL)	Measured Volume (mL)
00:03:00	00:03:00	00:03:00	400*	408

Theoretical Retentate Composition

Percentage (%)
Cells 18.8
Supernatant 41
Solution 1 81.1
Solution 2 0.1
Total 100

PROCEDURE PARAMETERS

General Parameters	Source Rise Volume (mL)	Pause After Source Rise	Enabled	Min Source
Spinner Idle Rate (RPM)	600	40	Enabled	Min Source
Final Product Media Susp. Rate (mL/min)	100	Pause After Source Rise Test	IP Top Port Rinse Volume (mL)	20
High Pressure Limit (mmHg)	500	IP Bottom Port Rinse Volume (mL)	Final IP Bottom Port Rinse Volume (mL)	10
Low Pressure Limit (mmHg)	20			
Disposable Kit Prime Solution	Solution 1			

Source Prime Parameters

Prime 1	Prime 2	Prime 3
Volume (mL)	100	100
Flow Rate (mL/min)	100	100
Pauses After Prime Test	Disabled	Disabled
Pauses After Prime Test	Disabled	Disabled

Container Information

Type	Location	Cap (mL)
Source	On-Scale*	1000*
Final Filtrate	On-Scale*	2500*
Retentate	On-Scale*	600*

Procedure Record Key Fresenius Kabi Printed On: 10/27/2021 12:07:52 PM Page: 2 of 6

What is included?

- Secure wired or wireless data transfer directly from the Lovo
- Non-editable Procedure reports documenting programmed parameters, procedure results, calibration and events times (exportable to PDF or Excel)
- Filterable procedure listings providing a historical view of procedures from all devices (exportable from DXT to Excel or LIMS)

PROCEDURE NOTES

User ID	Date / Time	Description
---------	-------------	-------------

PROCEDURE EVENTS

User ID	Date / Time	Name	Type***	Alert
User 1	4/13/2021 11:12 AM	Kit Install Complete	0	
User 1	4/13/2021 11:12 AM	Changed User ID->rnkm	2	
User 1	4/13/2021 11:13 AM	Alert 2016 Unable to Pressurize Kit 5 6	1	

Code	2016
Class	ALERT
Data 1	5
Data 2	6

Instrument features

Cell types

Fresh, cryo-preserved, or culture-expanded white blood cells, including, but not limited to, leukapheresis CD34⁺ cells, CAR T-cells, TILs, NK cells, and MSCs.

Volume range

Source Up to 22 L
Output¹ 50 mL – 50 L

Wash-out range

- Up to 99.9999%²

System components

- 73 lb, 35.3" × 17.6" × 24.5" (W × D × H) benchtop instrument
- Single-use processing kit with spinning membrane module

¹Actual lowest achievable volume will depend on cell type, cell concentration, and source volume.

²Based on theoretical wash-out from system estimator.



Ordering Information

Description	Quantity	Code
Lovo Cell Processing System	N/A	6R4900
Lovo Cell Processing Disposable Kit with Bag Access – 4µm (Compatible with Lovo software version 3.0 and 3.2)	6 units/case	X6R4909A
Lovo Cell Processing Disposable Kit – 4µm (Compatible with Lovo software versions 2.0, 3.0 and 3.2)	6 units/case	X6R4906A
Lovo Ancillary Bag Kit	20 units/case	X6R4902
Lovo Pouch Kit	6 units/case	X6R4907
Lovo Valve and Filter Disposable Kit	6 units/case	X6R4917
20mm Vialok Vented Vial Access Device	100 units/case	YM020

The Lovo Cell Processing System is for laboratory use only and may not be used for direct transfusion. Appropriate regulatory clearance is required by the user for clinical use. Refer to the Lovo Cell Processing System Operator's Manual for a complete list of warnings and precautions associated with the use of this device. For additional information, please visit scaleready.com/lovo.

scaleready.com

Contact us: info@scaleready.com

ScaleReady is a Joint Venture formed by Bio-Techne, Fresenius Kabi, and Wilson Wolf. Combining selected offerings from the three partners, the ScaleReady manufacturing platform combines tools and technologies for cell culture, cell activation and expansion, gene editing, and cell processing.

All products are for research use or manufacturing purposes only. Lovo is manufactured by Fresenius Kabi. Copyright © 2023 ScaleReady USA, LLC. All rights reserved. Trademarks referred to are property of their respective owners.

biotechne®

FRESENIUS
KABI

WILSONWOLF™

0101-LOVO-01-10/21
L116

Choose
Lovo

To increase
the efficiency of
your cell therapy
manufacturing
process

References

- Lovo 2.X Blood Run Protocol Report: 223-DER-048957 – Data on file at Fresenius Kabi USA.
- Lovo 2.X Product Quality Test Results Design Review: 223-DER-048958 – Data on file at Fresenius Kabi USA.
- Lovo New Membrane Cultured Cell Testing Results: 223-DER-066723 – Data on file at Fresenius Kabi USA.
- B.Mfarrej, *et al.* Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. *Cytotherapy*, Volume 19, Issue 12, 1501-1508.

ScaleReady